Pine Pharmaceuticals is pleased to introduce StaClear® Luer Slip and NORM-JECT® Less Fill, our all-new syringe options for repackaged bevacizumab. Designed to provide exceptional quality, StaClear® Luer Slip and NORM-JECT® Less Fill syringes now offer a low dead space...
Company news
Business First recognizes Pine Pharmaceuticals during 2023 Manufacturing Awards
We are pleased to announce that Buffalo Business First has named Pine Pharmaceuticals a 2023 Manufacturer Award winner. This award recognizes Pine as one of the top family-run businesses in the manufacturing industry and honors owners Al Sr. and Alfonse J. Muto for...
Pine Pharmaceuticals assumes Athenex’s 503B business, preserving over 50 jobs, expanding its product offerings, and serving hospitals and health systems nationwide
Tonawanda, NY, May 3, 2023 /PRNewswire/– Pine Pharmaceuticals, one of the nation's largest and most trusted FDA-registered 503B outsourcing facilities, today announced the successful integration of Athenex's 503B business, including the transfer of people, processes,...
Pine owners recognized as one of the top Family Businesses of 2022
Buffalo Business First has named Pine Pharmaceuticals a 2022 Family Business Award winner. This recognition will honor owners Al Sr. and Alfonse J. Muto as one of the top multi-generational, family-owned businesses in Western New York. In early 1985, Al Sr. founded...
Introducing: TPC+K and TPC+T Combination Drops
Now joining our family of top-selling combination drops, Pine Pharmaceuticals is excited to announce our latest product innovations in ophthalmology: TPC+K and TPC+T. Working diligently to keep our promise, we listened to your feedback and carefully...
Pine announces expansion completion, tripling facility size and doubling workforce
After the announcement of our expansion in December 2021, Pine Pharmaceuticals is pleased to share the completion of our 50,000-square-foot state-of-the-art facility. Designed to comply with the US Food and Drug Administration's Current Good Manufacturing Practice...
Owners Al Sr. and Alfonse J. Muto recognized for second consecutive year as Fast 46 finalists
After being recognized in 2021, we are excited to share that Pine Pharmaceuticals' owners Al Sr. and Alfonse J. Muto will be honored at The University at Buffalo's 2022 "Fast 46" ceremony for a second consecutive year! Named in honor of UB's founding in 1846, Fast 46...
University at Buffalo recognizes owners Al Sr. and Alfonse J. Muto
The University at Buffalo recently recognized Pine Pharmaceuticals owners Al Sr. and Alfonse J. Muto during their inaugural "Fast 46" program. Named in honor of UB's founding in 1846, Fast 46 recognizes and celebrates the success of 46 of the fastest-growing...
Cyclopentolate is on the FDA’s Drug Shortage List – combination drops still available
Despite the recent inclusion of Cyclopentolate to the FDA’s Drug Shortage List, Pine Pharmaceuticals has combination ophthalmic drops in-stock and ready to ship. Both TPC Drops and Tropi-Phen are offered in convenient, cost-effective multi-use bottles and are kept at...
Pine Pharmaceuticals announces massive new expansion, tripling footprint
Pine Pharmaceuticals is pleased to announce the expansion of our 503B outsourcing facility located at 355 Riverwalk Parkway in Tonawanda, NY. Originally built in 2018, our facility will triple in size to meet our tremendous growth and provide an unprecedented level of...